Markus Raderer

机构：Medical University of Vienna

发表论文 116 篇 · 总被引 4060 次 · h-index 26

代表论文

• Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study (2015 · The Lancet · 被引 1294)
• Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders (2021 · Cancer Discovery · 被引 215)
• PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL) (2013 · Clinical Neuropathology · 被引 118)
• Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response (2012 · Haematologica · 被引 109)
• Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (2017 · The Lancet Oncology · 被引 87)
• Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary (2017 · Neuroendocrinology · 被引 51)